Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative
Morningstar has lowered its fair value estimate for Pfizer stock from USD 34 to USD 32 per share, following the company's 2025 earnings report. The adjustment is due to an impairment charge partly related to Seagen pipeline programs and mixed tolerability data from the Metsera obesity program MET-097i (PF’3944), leading to reduced long-term growth and margin expectations. Despite these concerns, Pfizer's shares appear undervalued given the current market sentiment.
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative
Morningstar has lowered its fair value estimate for Pfizer stock to USD 32 from USD 34 per share, citing a USD 4.4 billion impairment related to Seagen pipeline programs and mixed tolerability data for the Metsera obesity drug candidate, MET-097i. Despite a 2% revenue decline and 4% adjusted EPS increase in 2025, the company's cost-cutting leverage is diminishing, making future growth heavily reliant on a few key products. The market currently undervalues Pfizer shares due to weak sentiment, despite the lowered long-term growth and margin expectations.
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative
Morningstar has lowered its fair value estimate for Pfizer (PFE) stock from $34 to $32 per share after the company reported a 2% decline in 2025 revenue and an unexpected impairment charge related to Seagen pipeline programs. Additionally, new data from Pfizer's Metsera obesity program showed a roughly 9% discontinuation rate due to adverse events, raising concerns about the program's long-term potential. Despite these challenges, Morningstar's analysis suggests Pfizer's shares remain undervalued given weak market sentiment.
Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity
Analysts are questioning the competitiveness of Pfizer's monthly GLP-1 drug for obesity, despite positive Phase IIb data. While the data shows the drug is competitive, experts believe it is not best in class when compared to existing treatments. This raises concerns about Pfizer's ability to challenge market leaders in the obesity treatment space.
Pfizer stock dips on Metsera mid-stage trial results
Pfizer's stock declined over 3% following the release of mid-stage trial results for its newly acquired company, Metsera. The Phase 2 trial for Metsera's MET-097i (now PF-3944), a weight-loss drug, showed a weight reduction of up to 10.5% after six months. This efficacy fell slightly short of Eli Lilly's competing drug, Zepbound.
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Pfizer unveiled early Phase IIb data for its obesity candidate PF’3944, showing 12.3% weight loss at week 28 with monthly dosing, which analysts found less competitive compared to Eli Lilly's Zepbound. Despite the limited data release and analysts' questions, Pfizer is advancing the drug to Phase III trials, with executives asserting confidence in its potential for competitive efficacy and a positive safety profile. The company expects more detailed results to be presented at the American Diabetes Association conference in June.
Pfizer dips on new data for obesity drug acquired in $10B deal
Pfizer's shares dropped after new Phase 2 trial data for its obesity drug, PF’3944, showed it was "slightly inferior" to Eli Lilly's Zepbound, despite leading to significant weight loss compared to a placebo. The drug, acquired for $10 billion, will proceed to Phase 3 trials later this year with a higher dose, which executives believe will improve efficacy. The company is betting on its monthly maintenance dosing strategy to offer convenience and improve patient adherence in a competitive weight loss market.
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push
Pfizer is strategically reshaping its portfolio by acquiring obesity drug developer Metsera for $10 billion, signaling a re-entry into the weight loss market. The company also announced a broader R&D focus on oncology and immunology, alongside a new vaccine adjuvant licensing agreement with Novavax. These moves aim to diversify Pfizer's business as COVID-related revenues decline and patent expirations loom, focusing on new growth areas for future success.
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
Pfizer has released its initial weight-loss data for PF’3944, an injectable GLP-1 asset acquired from Metsera, showing up to 12.3% placebo-adjusted weight loss at 28 weeks in a Phase IIb study. Analysts at BMO Capital Markets consider these results "competitive" compared to other available therapies like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide. Pfizer is planning an "expansive" Phase III program for PF’3944, including studies for various patient populations and potential combination regimens.
Pfizer beats sales estimates on demand for older drugs
Pfizer surpassed fourth-quarter sales expectations driven by its established drugs, offsetting declines in its Covid vaccine and treatment franchises. The company is actively pursuing new growth avenues, including a significant investment in obesity startup Metsera, which has shown promising early results for one of its weight-loss drugs. Despite these successes, many of Pfizer's key products face increasing competition and pricing pressures.
Pfizer beats sales estimates on demand for older drugs
Pfizer exceeded fourth-quarter sales expectations driven by strong performance from its older drugs, compensating for decreased demand for its Covid-19 vaccine and treatment. The company is actively seeking new growth avenues, including the acquisition of obesity startup Metsera and reported promising early data for one of Metsera's weight-loss drugs. Despite facing increased competition for blockbusters like Prevnar and Vyndaqel and price cuts for Eliquis, these drugs largely met sales expectations, while Covid-19 product sales saw a significant decline from the previous year.
Metsera Acquisition May Put Korean Obesity Assets Under Global Spotlight
The acquisition of Metsera has drawn attention to Korean obesity assets, particularly those involving GLP-1, oral, poly agonist, and new modality contenders. Hanmi’s first obesity drug, efpeglenatide, is currently in the Korean approval stage. This development suggests that Korean pharmaceutical companies are making significant strides in the obesity drug market.
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025
The biopharma sector concluded 2025 with robust M&A activity in Q4, signaling a stronger transactional trend compared to 2024. Data from Evaluate Pharma indicates this positive finish for the year.
Key facts: Novo Nordisk seeks obesity deals after Metsera loss; CEO notes price cuts' impact
Novo Nordisk is actively looking for new deals to boost its obesity portfolio after losing a bid for Metsera. The CEO, Mike Doustdar, also noted that recent price reductions for obesity medications would quickly affect Novo Nordisk's market, despite the long-term goal of treating more patients.
JPM conference notebook: After Metsera, Novo Nordisk open to more deals
Novo Nordisk's CEO, Mike Doustdar, stated at the JPMorgan Healthcare Conference that the company is open to more mergers and acquisitions despite losing the bid for obesity drugmaker Metsera. This indicates a positive outlook for biotech companies, as several pharmaceutical giants are looking to acquire in the coming year.
BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera
Bank of America analyst Jason Gerberry lowered Pfizer's price target to $27 from $28, maintaining a Neutral rating, due to a steeper-than-expected erosion of its COVID-19 franchise and a shift in focus to its obesity strategy with Metsera. Despite this, Pfizer and Astellas announced positive Phase 3 trial results for PADCEV and Keytruda in muscle-invasive bladder cancer, positioning it as a potential platinum-free standard of care. The company continues to develop biopharmaceutical products globally, with investor attention now on its obesity pipeline and oncology advancements.
Pfizer ’26 Guidance Puts Emphasis On The Long Term For A Return To Growth
Pfizer's 2026 guidance emphasizes a long-term strategy for returning to growth. The company is focusing on future initiatives and developments to achieve this goal. This guidance signals a patient outlook towards regaining strong performance in the coming years.
6 Biotechs That Could Be Big Pharma’s Next M&A Target
The recent bidding war for Metsera has signaled to analysts that Big Pharma is actively seeking new biotech acquisitions, intensifying the search for the next M&A target. Six biotechs are currently generating significant M&A buzz, including Maplight Therapeutics due to setbacks for Bristol Myers Squibb's competing muscarinic drug, and Structure Therapeutics with its promising GLP-1 data. Other biotechs highlighted are Abivax for its inflammatory disease candidates, Terns Pharmaceuticals after "unprecedented" oncology data, Ventyx Biosciences with its NLRP3 inhibitors, and Viking Therapeutics, a long-standing M&A prospect in the obesity space.
Pfizer Sues to Block Novo Bid for Obesity Drugmaker Metsera
Pfizer has filed a lawsuit to block Novo Nordisk's bid for Metsera, an obesity drugmaker, citing concerns over intellectual property. The legal action aims to prevent the acquisition, which could intensify competition in the rapidly growing obesity treatment market. This move highlights the fierce rivalry among pharmaceutical giants in the race for innovative weight-loss therapies.
Pfizer Follows $10bn Metsera Purchase By Licensing YaoPharma Obesity Asset
Pfizer is continuing to expand its obesity portfolio following its recent $10 billion acquisition of Metsera. The company has now entered into a licensing deal with YaoPharma for an obesity asset, further solidifying its presence in the competitive obesity treatment market. This move suggests Pfizer's commitment to developing new therapies in this therapeutic area.
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
Pfizer has entered a licensing deal with Chinese firm YaoPharma, a subsidiary of Fosun Pharma, for an investigational GLP-1 receptor agonist, YPO5002, worth up to $1.9 billion. This comes after Pfizer's recent high-profile acquisition of Metsera to bolster its obesity pipeline. The deal involves an initial $150 million upfront payment, with Pfizer taking over development, manufacturing, and commercialization after YaoPharma completes an ongoing Phase I trial of YPO5002.
November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and More
This article provides a round-up of Pfizer's social media activities in November, highlighting third-quarter earnings, the acquisition of Metsera, and various initiatives. Key announcements include CEO Albert Bourla's update on the Metsera acquisition and strong Q3 results, as well as new video series launches and the Pfizer Foundation's 2025 Citizens Award win. The article also touches on awareness campaigns for lung cancer and efforts to promote vaccination against respiratory illnesses.
Pfizer wins bidding war for Metsera with $10B offer
Pfizer has successfully acquired Metsera for over $10 billion, ending a bidding war with Novo Nordisk for the obesity drug developer. Metsera abandoned Novo Nordisk's offer, which raised regulatory concerns, to accept Pfizer's new proposal of up to $86.25 per share. The deal, which has FTC clearance, is expected to give Pfizer a strong position in the competitive obesity drug market.
Metsera Accepts Pfizer’s $10B Offer
Metsera has accepted Pfizer's $10 billion acquisition bid, valuing the company at up to $86.25 per share. This agreement, which includes cash and a contingent value right, grants Pfizer entry into the lucrative weight-loss drug market. The Metsera Board of Directors endorsed the Pfizer offer, citing superior terms and lower regulatory risks compared to a withdrawn bid from Novo Nordisk.
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Pfizer has completed the acquisition of biotech firm Metsera for up to $10 billion, securing its entry into the rapidly expanding obesity treatment market after a competitive bidding war with Novo Nordisk. Metsera, a clinical-stage company, focuses on developing treatments for obesity and metabolic diseases, including a once-monthly injectable GLP-1 receptor agonist and an oral GLP-1 candidate. This acquisition positions Pfizer to compete with market leaders like Eli Lilly and Novo Nordisk, who currently dominate the weight-loss drug market.
Metsera falls after accepting up to $10 billion offer from Pfizer
Shares of Metsera fell over 15% after the weight-loss drug developer accepted Pfizer's up to $10 billion offer, ending a bidding war with Novo Nordisk. Pfizer's sweetened deal, which includes an upfront payment and performance-contingent milestones, gives it entry into the lucrative obesity drug market. Metsera chose Pfizer's bid citing antitrust risks with Novo's offer, despite previously calling Novo's proposal superior.
Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal
Metsera's shares plummeted by about 15% after Novo Nordisk withdrew its bid, leaving Pfizer to secure a revised merger agreement for the weight-loss biotech. The deal values Metsera at up to $86.25 per share in cash, with Metsera citing rising antitrust risks from Novo Nordisk's competing proposal as a reason for accepting Pfizer's "superior" offer. This ends a fierce acquisition battle, with investors reacting to the shift from a potential bidding war to a single-buyer scenario, lowering expectations for a higher takeover premium.
Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits
Pfizer has secured obesity drug developer Metsera for $10 billion, overcoming a bidding war with Novo Nordisk. This acquisition gives Pfizer a significant entry into the lucrative obesity drug market, despite Metsera's treatments being years from market. Novo Nordisk withdrew its bid, citing U.S. antitrust risks and stating it would focus on its own pipeline development.
Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera
Novo Nordisk has launched a rival bid of up to $8.5 billion for U.S. obesity biotech firm Metsera, attempting to hijack an offer from Pfizer. Metsera has deemed Novo's bid superior, signaling an aggressive move by Novo Nordisk to bolster its pipeline in the competitive weight-loss drug market. Pfizer has criticized Novo's bid as "reckless" and raised antitrust concerns.
Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge - Yahoo Finance
Metsera (MTSR) has experienced a significant 48% share price surge over the past month, leading investors to question its current valuation. The company trades at a Price-to-Book ratio of 12.4x, which is considerably higher than industry and peer averages, suggesting market optimism for future growth despite current unprofitability and lack of revenue. Investors are advised to consider the risks associated with this premium valuation and to conduct further research.
Metsera raises $215m in Series B round for weight loss candidates
Metsera has successfully raised $215 million in a Series B funding round, bringing its total funding to over $500 million in seven months, to advance its portfolio of GLP-1RA candidates for weight loss. The company has a lead asset, MET-097i, which showed positive Phase I data and is now in Phase II trials, alongside two other clinical candidates, MET-233i and an oral drug MET-002. This significant investment positions Metsera to compete in the rapidly growing weight loss treatment market, with GLP-1RA therapies projected to reach $168 billion in sales by 2033.
Metsera Secures $215 Million Series B Financing
Metsera, Inc., a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, announced the close of a $215 million Series B financing round. This funding will advance its portfolio of Nutrient-Stimulated Hormone analog peptides, including ongoing Phase 2 trials for MET-097i and newly initiated clinical trials for MET-233i and MET-002. Leading investors like Wellington Management and Venrock Healthcare Capital Partners backed the financing, bringing Metsera's total funding to over $500 million.
Latham & Watkins Advises Metsera in Strategic Collaboration With Amneal
Latham & Watkins advised Metsera, a clinical-stage biopharmaceutical company, in a collaboration agreement with Amneal Pharmaceuticals. The agreement outlines Amneal as Metsera’s preferred supply partner for developed markets and grants Amneal a license to commercialize Metsera’s products in select emerging markets. Amneal will invest between US$150 million and US$200 million in establishing new manufacturing facilities in India to support this partnership.
Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097
Metsera announced positive topline Phase 1 clinical trial results for MET-097, a potential once-monthly injectable GLP-1 receptor agonist, showing significant and durable weight loss. The drug achieved a 7.5% body weight reduction at day 36, with weight loss continuing for at least four weeks after the last dose, and demonstrated a 380-hour half-life. These results support a potential once-monthly dosing regimen without titration, and Metsera plans to initiate Phase 2b trials in Q4 2024.
With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments
Metsera, an Arch-backed biotech, has emerged from stealth with $290 million in Series A funding to develop next-generation obesity and metabolic disease medicines. The company aims to create customizable combination treatments using a library of gut hormone peptides and oral absorption technology, including clinical-stage assets and an extensive preclinical pipeline. Metsera believes combination therapies with a GLP-1 backbone are the future, aiming to offer improved effectiveness, tolerability, and weight maintenance compared to existing treatments.
GLP-1 start-up Metsera launches with $290 million
Metsera, a GLP-1 focused start-up founded by Clive Meanwell (formerly of The Medicines Company), has launched with $290 million in funding. The company is developing a suite of peptide drugs for weight loss and other indications, leveraging an acquisition of Zihipp Limited for its extensive gut hormone peptide library. Metsera's strategy includes injectable and oral GLP-1 receptor agonists, with some already in Phase 1 clinical trials.
Metsera Launches with Focus on Medicines for Obesity & Metabolic Diseases
Metsera Inc., a clinical-stage biopharmaceutical company, has officially launched with a focus on developing medicines for obesity and metabolic diseases. The company, founded by Population Health Partners and ARCH Venture Partners, is advancing a portfolio of oral and injectable incretin, non-incretin, and combination therapies. Metsera aims to address the future needs of the weight loss treatment landscape, emphasizing effective weight maintenance, muscle preservation, less-frequent dosing, and improved efficacy and tolerability.
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
Metsera, a new biotechnology startup, has launched with $290 million in funding to develop a portfolio of weight loss drugs intended to compete with market leaders like Eli Lilly and Novo Nordisk. The company aims to create "second, third, or even fourth generation" obesity medicines, with two therapies already in clinical testing and more to follow. Metsera's strategy involves acquiring drug prospects and forming licensing pacts to build a diverse pipeline, including oral and injectable drugs that target multiple gut hormones.
Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases
Metsera, a clinical-stage biopharmaceutical company, has launched with $290 million in financing to develop next-generation medicines for obesity and metabolic diseases. The company, founded by Population Health Partners and ARCH Venture Partners, is advancing a broad portfolio of oral and injectable therapies. Metsera's pipeline includes GLP-1 receptor agonists, DACRAs, unimolecular GGGs, and an oral peptide delivery platform, aiming to address critical needs in weight loss, maintenance, and disease prevention.
